Description

8-(2-Methoxycarbonylamino-6-Methylbenzyloxy)-2-Methyl-3-(2-Propynyl)Imidazo(1,2-A)Pyridine is a high-purity, advanced pharmaceutical intermediate with a complex heterocyclic structure. This compound is valued for its role as a critical building block in the synthesis of novel active pharmaceutical ingredients (APIs), particularly in therapeutic areas requiring targeted molecular design. It is essential for research institutions, contract development and manufacturing organizations (CDMOs), and pharmaceutical companies engaged in the development of new chemical entities.

Application

• Pharmaceutical Intermediate: A key precursor in the multi-step synthesis of proprietary drug candidates, especially in central nervous system (CNS) and anti-inflammatory research.
• Medicinal Chemistry Research: Serves as a versatile scaffold for structure-activity relationship (SAR) studies and lead optimization in drug discovery programs.
• API Development: Used in process development and scale-up for new active pharmaceutical ingredients under current Good Manufacturing Practice (cGMP) standards.
• Contract Synthesis: Supplied to CDMOs for custom synthesis projects requiring high-purity, complex heterocyclic compounds.
• Biochemical Research: Potential use as a tool compound or probe in biochemical assays to study specific enzyme or receptor interactions.

Basic Information

Product Name	8-(2-Methoxycarbonylamino-6-Methylbenzyloxy)-2-Methyl-3-(2-Propynyl)Imidazo(1,2-A)Pyridine
CAS No.	117525-13-0
Molecular Formula	C20H21N3O3
Molecular Weight	351.40 g/mol
Synonyms	8-[(2-[(Methoxycarbonyl)amino]-6-methylphenyl)methoxy]-2-methyl-3-(2-propyn-1-yl)imidazo[1,2-a]pyridine; 8-(2-Methoxycarbonylamino-6-methylbenzyloxy)-2-methyl-3-prop-2-ynylimidazo[1,2-a]pyridine; Imidazo[1,2-a]pyridine, 8-[[2-[(methoxycarbonyl)amino]-6-methylphenyl]methoxy]-2-methyl-3-(2-propyn-1-yl)-; Zaleplon Impurity; Zaleplon Related Compound
EINECS	Contact for details

Quality Control

Our production of this advanced intermediate adheres to stringent quality systems suitable for pharmaceutical development. Certificates of Analysis (COA) are provided with each batch, detailing purity, identity, and impurity profiles. Quality is assured through analytical methods including HPLC, GC, and NMR spectroscopy. We support development under cGMP guidelines and can tailor specifications to meet the specific requirements of your research or regulatory filing.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (typically 15-25°C). The compound may be hygroscopic; therefore, containers should be kept tightly sealed in a dry environment to prevent moisture uptake.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Purity (HPLC)	≥ 98.0%
Related Substances (HPLC)	Individual impurity ≤ 0.5% Total impurities ≤ 2.0%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Water Content (KF)	≤ 0.5%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.